Should Revlimid Be Held During Salmonella Bacteremia Treatment?
Yes, lenalidomide (Revlimid) should be temporarily held while treating active Salmonella bacteremia, then resumed at the physician's discretion once the infection has resolved or is adequately controlled.
Rationale Based on FDA Labeling and Clinical Evidence
The FDA label for Revlimid explicitly addresses dose modifications for non-hematologic toxicities: "For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician's discretion at next lower dose level when toxicity has resolved to Grade 2 or below" 1. While this guidance specifically addresses toxicities caused by lenalidomide, the principle of holding therapy during serious infections is standard practice given lenalidomide's immunosuppressive effects.
Key Supporting Evidence
Lenalidomide significantly increases infection risk:
- Meta-analysis data demonstrates that lenalidomide use is associated with a 2.23-fold increased relative risk of high-grade infections (95% CI: 1.71-2.91, P < 0.0001) 2
- Critically, fatal infection events occurred only in lenalidomide-treated patients, with no infection-related deaths in control groups 2
- The overall incidence of high-grade infection with lenalidomide is 14.32% 2
Infection remains a major cause of morbidity and mortality in myeloma patients:
- Recent consensus guidelines emphasize that infection is a significant contributor to both morbidity and mortality in multiple myeloma patients 3
- The immunomodulatory effects of lenalidomide, while therapeutically beneficial, create vulnerability during active bacterial infections 4, 5
Clinical Management Algorithm
During Active Bacteremia:
- Immediately hold lenalidomide when Salmonella bacteremia is diagnosed
- Initiate appropriate antibiotic therapy for Salmonella (typically fluoroquinolones or third-generation cephalosporins)
- Monitor for clinical improvement and resolution of bacteremia with repeat blood cultures
Criteria for Resumption:
- Clinical stability: Resolution of fever and systemic symptoms
- Microbiologic clearance: Negative repeat blood cultures
- Adequate antibiotic course: Typically 7-14 days for uncomplicated bacteremia
- Consider resuming at reduced dose (next lower dose level per FDA guidance) 1
Post-Infection Monitoring:
- Resume with close monitoring for infection recurrence
- Weekly CBC monitoring initially to assess for neutropenia, which increases infection susceptibility 1
- If neutropenia develops (ANC <1,000/mcL), follow FDA dose modification guidelines 1
Important Caveats
Balance myeloma control with infection risk: While holding lenalidomide temporarily is prudent during active bacteremia, the duration should be minimized to maintain myeloma disease control. The guidelines emphasize continuous therapy for optimal outcomes 6, so resumption should occur as soon as safely feasible.
Consider prophylaxis upon resumption: Given the increased infection risk with lenalidomide 2, 7, discuss antimicrobial prophylaxis strategies per institutional protocols and recent consensus guidelines 3.
Neutropenia compounds risk: If the patient develops lenalidomide-induced neutropenia (common adverse effect), this further increases infection susceptibility and may require dose reduction even after infection resolution 1, 7.
Individual risk assessment: Patients with multiple high-risk features (advanced age, renal impairment, prior infections) warrant particularly cautious resumption with potentially longer holds and lower restart doses 8, 9.